Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
RGCC was launched in 2004 by genetics pioneer
Dr. Ioannis Papasotiriou with a view to developing personalized treatment options to treat cancer effectively.
His belief that personalized medicine using the information in a patient’s genes is the way forward lies at the very heart of everything we do.
Our liquid biopsies represent a transformative approach to cancer testing and research, offering distinct advantages over traditional tissue biopsies. Minimally invasive and more convenient, liquid biopsies involve a simple blood draw, making them patient-friendly. Moreover, they are cost-effective, enhancing accessibility for patients and healthcare practitioners alike.
Additionally, unlike traditional biopsies that offer insights from one specific location in the body, liquid biopsies capture information from distant (metastatic) sites as well. This means that liquid biopsies paint a complete picture of cancer throughout the patient's body, offering a comprehensive perspective that can be invaluable for precise diagnosis and treatment planning.
At RGCC, we understand that treatment options go beyond traditional chemotherapy. Our tests evaluate the effectiveness of over 50 chemotherapeutic agents alongside natural substances. This holistic approach not only expands treatment options for you to choose from, it also helps identify treatments that work best for you!
Liquid biopsies provide a comprehensive, real-time view of a patient’s cancer status. Frequent testing allows continuous monitoring, facilitating prompt adjustments to treatment plans.
These tests also reveal the genetic composition of the cancer, enabling the identification of highly effective treatments tailored to individual biology. This personalized approach helps you choose treatments that will likely have the greatest chance of showing a positive result for your body and cancer.
Our commitment extends to advancing personalized medicine through relentless research and innovation. Our experts continually strive to develop new diagnostic and therapeutic options for cancer.
Our liquid biopsy tests analyze circulating tumor cells (CTCs) and associated biomarkers in the bloodstream. This provides comprehensive insights into a patient’s cancer, guiding treatment decisions and monitoring disease progression.
Our team is at the forefront of the quest for more personalized and precise cancer treatments. We are globally recognized as the leading center in the field of personalized medicine, developing cutting-edge technologies that can help identify the most effective treatments for each individual patient.
At RGCC, we are committed to providing innovative solutions for cancer and chronic diseases. Our global mission is to help patients across the world have access to the latest diagnostic and therapeutic options for their conditions.
Our state-of-the-art laboratory facilities in Europe are equipped with the latest technology and staffed by world-class experts.
Our scientists are dedicated to pioneering research that propels the field of personalized medicine forward. We use innovative techniques to provide timely and precise information so patients and their practitioners can take therapeutic action based on results that provide granular levels of detail about their condition.
At RGCC, we envision a future where cancer treatment is truly personalized and targeted to meet each patient’s unique needs. Through our research and innovation, we work tirelessly to turn this vision into reality, offering renewed hope to patients and their families worldwide.
Excellence is at the core of everything we do at RGCC, from the quality of our tests and protocols to the support we provide to patients and practitioners. Whether you’re a patient seeking hope or a healthcare professional dedicated to improving patient outcomes, we welcome the opportunity to collaborate and provide personalized solutions that make a real difference.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.
Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.
Learn more about RGCC at
https://rgcc-international.com/
Follow us on social media to find out the latest news and updates from our experts.
Facebook: https://www.facebook.com/profile.php?id=61554630098937
Instagram: https://www.instagram.com/rgcc_north_america/
LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
